Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.56 |
| ▸ | GSTO1 | P78417 | 4/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26624956 | 0.83 | GSTO1 (0.49) | BCL2A1GSTO1PSMB5TDP1AKR1B1 | |
| SCHEMBL14383487 | 0.81 | GSTO1 (0.48) | BCL2A1GSTO1PSMB5TDP1CYP1A2 | |
| SCHEMBL20314806 | 0.81 | GSTO1 (0.48) | BCL2A1GSTO1PSMB5TDP1 | |
| SCHEMBL17666071 | 0.81 | PSMB5 (0.51) | BCL2A1GSTO1PSMB5TDP1 | |
| SCHEMBL7104395 | 0.79 | ALDH1A1 (0.41) | BCL2A1TDP1AKR1B1TP53 | |
| SCHEMBL2992708 | 0.78 | GSTO1 (0.54) | BCL2A1GSTO1PSMB5TP53 | |
| SCHEMBL9134770 | 0.76 | GABRP (0.38) | BCL2A1TDP1AKR1B1TP53 | |
| SCHEMBL17666020 | 0.76 | GSTO1 (0.43) | BCL2A1GSTO1PSMB5TDP1 | |
| SCHEMBL7838834 | 0.75 | BCL2A1 (0.44) | BCL2A1TDP1TP53 | |
| SCHEMBL341820 | 0.74 | TDP1 (0.56) | TDP1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669289-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3201206-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-06-28 | — | — | US | disclosed |
| WO-2016050358-A1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669289-B2 | Boronic acid derivatives | BCL9, BCL9L, BCL6 | BCL2A1 54/4885GSTO1 2482/4885PSMB5 105/4885 |
| US-20180179232-A1 | BORONIC ACID DERIVATIVES | BCL9, BCL9L, BCL6 | BCL2A1 54/4885GSTO1 2482/4885PSMB5 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.